Peptides DB
Research-centric peptide and protocol reference hub
Study 11 of 15MGF (Mechano Growth Factor) literatureJournal of pharmaceutical and biomedical analysis2026

Site-specific N-glycosylation differences between two recombinant human hyaluronan and proteoglycan link protein 1 forms with distinct hyaluronan-proteoglycan linking activity.

The study found that rhH-1 has a 7.5-fold higher linking potency toward hyaluronan and proteoglycans compared to rhH-2, attributed to distinct N-glycosylation differences.

Read at Journal of pharmaceutical and biomedical analysisAdd to compare

Where it sits

this study against the rest of the mgf (mechano growth factor) corpus
2
Preclinical · this one
11
Observational
0
Open-label
1
Randomised
1
Reviews

Summary and findings

This study characterized two recombinant human hyaluronan and proteoglycan link protein 1 (HAPLN1) forms expressed in CHO cells. The linking potency of rhH-1 was found to be 7.5-fold higher than that of rhH-2, with EC50 values of 133.5 ng/mL and 994.8 ng/mL, respectively. The study highlights distinct site-specific N-glycosylation differences between the two forms.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
EC50 values of 133.5 ng/mL for rhH-1 and 994.8 ng/mL for rhH-2.2026

Abstract

The authors’ words, as Journal of pharmaceutical and biomedical analysis supplied them

Hyaluronan and proteoglycan link protein 1 (HAPLN1) is a glycoprotein that stabilizes hyaluronan-proteoglycan complexes and maintains extracellular matrix integrity. Two protein forms of HAPLN1 have been reported; however, their structural and functional distinctions remain poorly understood. Here, we characterized two recombinant human HAPLN1 (rhHAPLN1) forms expressed in CHO cells using in-gel glycomic and glycoproteomic analyses with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and nano-LC-MS/MS. SDS-PAGE resolved two protein forms: rhH-1 (∼44 kDa, 76.3%) and rhH-2 (∼40 kDa, 23.7%). Both forms exhibited identical amino acid sequences and shared two N-glycosylation sites (Asn<sup>6</sup> and Asn<sup>41</sup>), as confirmed by analysis of in-gel tryptic glycosylated and deglycosylated peptides. A total of 22 and 15 N-glycans were identified in rhH-1 and rhH-2, respectively. At Asn<sup>6</sup>, rhH-1 contained highly branched, sialylated N-glycans (50.0%, normalized to 100% for each site), whereas rhH-2 showed low occupancy (3.7%) with non-sialylated N-glycans. In contrast, Asn<sup>41</sup> exhibited nearly identical profiles in both forms, comprising predominantly bi-antennary, highly sialylated N-glycans (84.0% in rhH-1 and 83.9% in rhH-2). Mild formic acid preserved tri/tetra-sialylation during N-glycopeptide recovery, and higher-energy collisional dissociation at two normalized collision energies improved N-glycan/peptide fragmentation for confident N-glycopeptide identification. Functional assays demonstrated that rhH-1 displayed 7.5-fold higher linking potency (EC<sub>50</sub> values of 133.5 ng/mL for rhH-1 and 994.8 ng/mL for rhH-2) toward hyaluronan and proteoglycans than rhH-2, while both showed similar efficacy (E<sub>max</sub>). This study provides the first comprehensive structural and functional comparison of sequence-identical rhHAPLN1 forms, revealing distinct site-specific N-glycosylation associated with differences in potency.

Elsewhere in the MGF (Mechano Growth Factor) corpus

BExperience of diabetes self-care and well-being among adults with type 2 diabetes in South Ethiopia: a qualitative descriptive study.International journal of qualitative studies on health and well-being · 2026 · n=21HumanAElastic tape as an add-on strategy to potentiate pulmonary rehabilitation outcomes in nonobese males with moderate-to-very severe COPD: A randomised clinical trial.Pulmonology · 2026 · n=42 · +329s ESWT improvement in ET group, exceeding MCID.HumanBInflammatory markers and the systemic immune-inflammation index in endometrial carcinoma and hyperplasia: a retrospective cohort study.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · n=238 · Adjusted odds ratio for NLR in EC versus controls was 2.06, 95% CI 1.04-4.09, p=0.037.HumanCPreclinical evaluation of PSMA-targeted ultrasound contrast agents in an orthotopic model of prostate cancer in rabbits.Bioactive materials · 2026 · MTT: 4.20 to 5.40-fold higher for PSMA-NBs compared to MBs.AnimalBDiagnostic performance of CDO1 and ZSCAN12 methylation in endometrial versus cervical samples for endometrial cancer and atypical hyperplasia: a comparative study.Annals of medicine · 2026 · 97.5% sensitivity for EC (39 of 40 evaluable cases)HumanCBiofilm forming capacity, sanitizer tolerance, and genetic characterization of persistent and non-persistent <i>Listeria monocytogenes</i> from artisan cheese processing environments.Biofilm · 2026 · 0-6 Single Nucleotide Polymorphisms (SNPs) different.In vitro